Market Overview:
The global prostacyclin market is expected to grow at a CAGR of 5.5% during the forecast period from 2018 to 2030. The growth in this market can be attributed to the increasing prevalence of PAH, rising geriatric population, and technological advancements in prostacyclin therapies. By type, the epoprostenol sodium segment is expected to account for the largest share of the global prostacyclin market in 2018. This segment is also projected to grow at a higher CAGR than other segments during the forecast period. By application, for injection is expected to account for the largest share of the global prostacyclin market in 2018.
Product Definition:
Prostacyclin is a hormone that helps keep blood vessels open. It is used to treat high blood pressure, heart disease, and other conditions caused by narrowed blood vessels.
Epoprostenol Sodium:
Epoprostenol sodium is a prostacyclin analog used to treat conditions associated with the cardiovascular and respiratory systems. It works by relaxing constricted blood vessels which reduces the workload on the heart and lungs.
Treprostinil:
Treprostinil is a prostacyclin analog. Prostacyclins are natural substances that help regulate the opening and closing of blood vessels by relaxing the muscular walls of the artery. The drug works by relaxing vascular smooth muscles to improve peripheral circulation and reduce peripheral vascular resistance, which results in an increased amount of circulating blood volume.
Application Insights:
The market is categorized on the basis of application into for injection, for oral, and for inhalation. The injectable form of prostacyclin dominated the global market in terms of revenue in 2017. This can be attributed to its high usage rate as compared to other forms such as topical or oral medications. For instance, while iloprost is available only by prescription in the U.S., epoprostenol sodium is available over-the-counter (OTC) throughout most parts of Europe and Asia Pacific countries due to which it accounts for a larger share among all applications globally.
Regional Analysis:
North America dominated the global prostacyclin market in 2017 owing to the presence of well-established healthcare infrastructure, high patient awareness levels coupled with relatively higher healthcare spending levels in this region. The U.S., which is one of the leading countries for drug development and approval, has approved several products for various applications such as eye drops, inhalation solution and tablets that are used for treating pulmonary hypertension. Europe also contributed significantly to market share in 2017 due to growing geriatric population base and increasing prevalence of cardiovascular diseases (CVDs).
Asia Pacific is expected to witness lucrative growth over the forecast period owing to rising disposable income resulting into increased demand for medical devices among patients suffering from CVDs or other heart conditions that require long-term therapy. Moreover, economic reforms undertaken by various governments have resulted into an increase in per capita income thereby driving consumer health expenditure towards treatment options such as prostacyclin analogues.
Growth Factors:
- Increasing incidence of pulmonary arterial hypertension (PAH) due to changing lifestyle and environmental factors.
- Growing awareness about the benefits of prostacyclin therapy among physicians and patients.
- Technological advancements in prostacyclin delivery systems that improve patient compliance and efficacy.
- Launch of novel prostacyclin therapies with better safety and efficacy profiles than existing products.
- Expansion of reimbursement coverage for prostacyclin therapy by private and government payers
Scope Of The Report
Report Attributes
Report Details
Report Title
Prostacyclin Market Research Report
By Type
Epoprostenol Sodium, Treprostinil, Iloprost, Beraprost Sodium
By Application
For Injection, For Oral, For Inhalation
By Companies
United Therapeutics, Actelion (J & J), GSK, Teva, Toray, Tide Pharma, Bayer AG
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
250
Number of Tables & Figures
175
Customization Available
Yes, the report can be customized as per your need.
Global Prostacyclin Market Report Segments:
The global Prostacyclin market is segmented on the basis of:
Types
Epoprostenol Sodium, Treprostinil, Iloprost, Beraprost Sodium
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
For Injection, For Oral, For Inhalation
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- United Therapeutics
- Actelion (J & J)
- GSK
- Teva
- Toray
- Tide Pharma
- Bayer AG
Highlights of The Prostacyclin Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Epoprostenol Sodium
- Treprostinil
- Iloprost
- Beraprost Sodium
- By Application:
- For Injection
- For Oral
- For Inhalation
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Prostacyclin Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Prostacyclin is a prostaglandin that is produced by the body in response to inflammation. Prostacyclin helps to reduce pain and swelling, and can help to speed up the healing process.
Some of the major companies in the prostacyclin market are United Therapeutics, Actelion (J & J), GSK, Teva, Toray, Tide Pharma, Bayer AG.
The prostacyclin market is expected to register a CAGR of 5.5%.
1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Prostacyclin Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. Prostacyclin Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. Prostacyclin Market - Supply Chain
4.5. Global Prostacyclin Market Forecast
4.5.1. Prostacyclin Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. Prostacyclin Market Size (000 Units) and Y-o-Y Growth
4.5.3. Prostacyclin Market Absolute $ Opportunity
5. Global Prostacyclin Market Analysis and Forecast by Type
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Type
5.2.2. Y-o-Y Growth Projections by Type
5.3. Prostacyclin Market Size and Volume Forecast by Type
5.3.1. Epoprostenol Sodium
5.3.2. Treprostinil
5.3.3. Iloprost
5.3.4. Beraprost Sodium
5.4. Absolute $ Opportunity Assessment by Type
5.5. Market Attractiveness/Growth Potential Analysis by Type
6. Global Prostacyclin Market Analysis and Forecast by Application
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Application
6.2.2. Y-o-Y Growth Projections by Application
6.3. Prostacyclin Market Size and Volume Forecast by Application
6.3.1. For Injection
6.3.2. For Oral
6.3.3. For Inhalation
6.4. Absolute $ Opportunity Assessment by Application
6.5. Market Attractiveness/Growth Potential Analysis by Application
7. Global Prostacyclin Market Analysis and Forecast by Sales Channel
7.1. Market Trends
7.2. Introduction
7.2.1. Basis Point Share (BPS) Analysis by Sales Channel
7.2.2. Y-o-Y Growth Projections by Sales Channel
7.3. Prostacyclin Market Size and Volume Forecast by Sales Channel
7.3.1. Manufacturer/Distributor/Service Provider
7.3.2. Aftermarket
7.4. Absolute $ Opportunity Assessment by Sales Channel
7.5. Market Attractiveness/Growth Potential Analysis by Sales Channel
8. Global Prostacyclin Market Analysis and Forecast by Region
8.1. Market Trends
8.2. Introduction
8.2.1. Basis Point Share (BPS) Analysis by Region
8.2.2. Y-o-Y Growth Projections by Region
8.3. Prostacyclin Market Size and Volume Forecast by Region
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. Asia Pacific
8.3.5. Middle East and Africa (MEA)
8.4. Absolute $ Opportunity Assessment by Region
8.5. Market Attractiveness/Growth Potential Analysis by Region
8.6. Global Prostacyclin Demand Share Forecast, 2019-2026
9. North America Prostacyclin Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.2. North America Prostacyclin Market Size and Volume Forecast by Country
9.2.1. U.S.
9.2.2. Canada
9.3. Absolute $ Opportunity Assessment by Country
9.4. North America Prostacyclin Market Size and Volume Forecast by Application
9.4.1. For Injection
9.4.2. For Oral
9.4.3. For Inhalation
9.5. Basis Point Share (BPS) Analysis by Application
9.6. Y-o-Y Growth Projections by Application
9.7. North America Prostacyclin Market Size and Volume Forecast by Type
9.7.1. Epoprostenol Sodium
9.7.2. Treprostinil
9.7.3. Iloprost
9.7.4. Beraprost Sodium
9.8. Basis Point Share (BPS) Analysis by Type
9.9. Y-o-Y Growth Projections by Type
9.10. Market Attractiveness/Growth Potential Analysis
9.10.1. By Country
9.10.2. By Product Type
9.10.3. By Application
9.10.4. By Sales Channel
9.11. North America Prostacyclin Demand Share Forecast, 2019-2026
10. Latin America Prostacyclin Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Latin America Average Pricing Analysis
10.2. Latin America Prostacyclin Market Size and Volume Forecast by Country
10.2.1. Brazil
10.2.2. Mexico
10.2.3. Rest of Latin America
10.3. Absolute $ Opportunity Assessment by Country
10.4. Latin America Prostacyclin Market Size and Volume Forecast by Application
10.4.1. For Injection
10.4.2. For Oral
10.4.3. For Inhalation
10.5. Basis Point Share (BPS) Analysis by Application
10.6. Y-o-Y Growth Projections by Application
10.7. Latin America Prostacyclin Market Size and Volume Forecast by Type
10.7.1. Epoprostenol Sodium
10.7.2. Treprostinil
10.7.3. Iloprost
10.7.4. Beraprost Sodium
10.8. Basis Point Share (BPS) Analysis by Type
10.9. Y-o-Y Growth Projections by Type
10.10. Market Attractiveness/Growth Potential Analysis
10.10.1. By Country
10.10.2. By Product Type
10.10.3. By Application
10.10.4. By Sales Channel
10.11. Latin America Prostacyclin Demand Share Forecast, 2019-2026
11. Europe Prostacyclin Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Europe Average Pricing Analysis
11.2. Europe Prostacyclin Market Size and Volume Forecast by Country
11.2.1. Germany
11.2.2. France
11.2.3. Italy
11.2.4. U.K.
11.2.5. Spain
11.2.6. Russia
11.2.7. Rest of Europe
11.3. Absolute $ Opportunity Assessment by Country
11.4. Europe Prostacyclin Market Size and Volume Forecast by Application
11.4.1. For Injection
11.4.2. For Oral
11.4.3. For Inhalation
11.5. Basis Point Share (BPS) Analysis by Application
11.6. Y-o-Y Growth Projections by Application
11.7. Europe Prostacyclin Market Size and Volume Forecast by Type
11.7.1. Epoprostenol Sodium
11.7.2. Treprostinil
11.7.3. Iloprost
11.7.4. Beraprost Sodium
11.8. Basis Point Share (BPS) Analysis by Type
11.9. Y-o-Y Growth Projections by Type
11.10. Market Attractiveness/Growth Potential Analysis
11.10.1. By Country
11.10.2. By Product Type
11.10.3. By Application
11.10.4. By Sales Channel
11.11. Europe Prostacyclin Demand Share, 2019-2026
12. Asia Pacific Prostacyclin Market Analysis and Forecast
12.1. Introduction
12.1.1. Basis Point Share (BPS) Analysis by Country
12.1.2. Y-o-Y Growth Projections by Country
12.1.3. Asia Pacific Average Pricing Analysis
12.2. Asia Pacific Prostacyclin Market Size and Volume Forecast by Country
12.2.1. China
12.2.2. Japan
12.2.3. South Korea
12.2.4. India
12.2.5. Australia
12.2.6. Rest of Asia Pacific (APAC)
12.3. Absolute $ Opportunity Assessment by Country
12.4. Asia Pacific Prostacyclin Market Size and Volume Forecast by Application
12.4.1. For Injection
12.4.2. For Oral
12.4.3. For Inhalation
12.5. Basis Point Share (BPS) Analysis by Application
12.6. Y-o-Y Growth Projections by Application
12.7. Asia Pacific Prostacyclin Market Size and Volume Forecast by Type
12.7.1. Epoprostenol Sodium
12.7.2. Treprostinil
12.7.3. Iloprost
12.7.4. Beraprost Sodium
12.8. Basis Point Share (BPS) Analysis by Type
12.9. Y-o-Y Growth Projections by Type
12.10. Market Attractiveness/Growth Potential Analysis
12.10.1. By Country
12.10.2. By Product Type
12.10.3. By Application
12.10.4. By Sales Channel
12.11. Asia Pacific Prostacyclin Demand Share, 2019-2026
13. Middle East & Africa Prostacyclin Market Analysis and Forecast
13.1. Introduction
13.1.1. Basis Point Share (BPS) Analysis by Country
13.1.2. Y-o-Y Growth Projections by Country
13.1.3. Asia Pacific Average Pricing Analysis
13.2. Middle East & Africa Prostacyclin Market Size and Volume Forecast by Country
13.2.1. Saudi Arabia
13.2.2. South Africa
13.2.3. UAE
13.2.4. Rest of Middle East & Africa (MEA)
13.3. Absolute $ Opportunity Assessment by Country
13.4. Middle East & Africa Prostacyclin Market Size and Volume Forecast by Application
13.4.1. For Injection
13.4.2. For Oral
13.4.3. For Inhalation
13.5. Basis Point Share (BPS) Analysis by Application
13.6. Y-o-Y Growth Projections by Application
13.7. Middle East & Africa Prostacyclin Market Size and Volume Forecast by Type
13.7.1. Epoprostenol Sodium
13.7.2. Treprostinil
13.7.3. Iloprost
13.7.4. Beraprost Sodium
13.8. Basis Point Share (BPS) Analysis by Type
13.9. Y-o-Y Growth Projections by Type
13.10. Market Attractiveness/Growth Potential Analysis
13.10.1. By Country
13.10.2. By Product Type
13.10.3. By Application
13.10.4. By Sales Channel
13.11. Middle East & Africa Prostacyclin Demand Share, 2019-2026
14. Competition Landscape
14.1. Global Prostacyclin Market: Market Share Analysis
14.2. Prostacyclin Distributors and Customers
14.3. Prostacyclin Market: Competitive Dashboard
14.4. Company Profiles (Details Overview, Financials, Developments, Strategy)
14.4.1. United Therapeutics
14.4.1.1. Overview
14.4.1.2. Financials
14.4.1.3. Developments
14.4.1.4. Strategic Outlook
14.4.2. Actelion (J & J)
14.4.2.1. Overview
14.4.2.2. Financials
14.4.2.3. Developments
14.4.2.4. Strategic Outlook
14.4.3. GSK
14.4.3.1. Overview
14.4.3.2. Financials
14.4.3.3. Developments
14.4.3.4. Strategic Outlook
14.4.4. Teva
14.4.4.1. Overview
14.4.4.2. Financials
14.4.4.3. Developments
14.4.4.4. Strategic Outlook
14.4.5. Toray
14.4.5.1. Overview
14.4.5.2. Financials
14.4.5.3. Developments
14.4.5.4. Strategic Outlook
14.4.6. Tide Pharma
14.4.6.1. Overview
14.4.6.2. Financials
14.4.6.3. Developments
14.4.6.4. Strategic Outlook
14.4.7. Bayer AG
14.4.7.1. Overview
14.4.7.2. Financials
14.4.7.3. Developments
14.4.7.4. Strategic Outlook
14.4.8. COMPANY8
14.4.8.1. Overview
14.4.8.2. Financials
14.4.8.3. Developments
14.4.8.4. Strategic Outlook
14.4.9. COMPANY9
14.4.9.1. Overview
14.4.9.2. Financials
14.4.9.3. Developments
14.4.9.4. Strategic Outlook
14.4.10. COMPANY 10
14.4.10.1. Overview
14.4.10.2. Financials
14.4.10.3. Developments
14.4.10.4. Strategic Outlook
14.4.11. COMPANY 11
14.4.11.1. Overview
14.4.11.2. Financials
14.4.11.3. Developments
14.4.11.4. Strategic Outlook
14.4.12. COMPANY 12
14.4.12.1. Overview
14.4.12.2. Financials
14.4.12.3. Developments
14.4.12.4. Strategic Outlook
14.4.13. COMPANY 13
14.4.13.1. Overview
14.4.13.2. Financials
14.4.13.3. Developments
14.4.13.4. Strategic Outlook
14.4.14. COMPANY 14
14.4.14.1. Overview
14.4.14.2. Financials
14.4.14.3. Developments
14.4.14.4. Strategic Outlook
14.4.15. COMPANY 15
14.4.15.1. Overview
14.4.15.2. Financials
14.4.15.3. Developments
14.4.15.4. Strategic Outlook
14.4.16. COMPANY 16
14.4.16.1. Overview
14.4.16.2. Financials
14.4.16.3. Developments
14.4.16.4. Strategic Outlook
14.4.17. COMPANY 17
14.4.17.1. Overview
14.4.17.2. Financials
14.4.17.3. Developments
14.4.17.4. Strategic Outlook
14.4.18. COMPANY 18
14.4.18.1. Overview
14.4.18.2. Financials
14.4.18.3. Developments
14.4.18.4. Strategic Outlook
14.4.19. COMPANY 19
14.4.19.1. Overview
14.4.19.2. Financials
14.4.19.3. Developments
14.4.19.4. Strategic Outlook
14.4.20. COMPANY 20
14.4.20.1. Overview
14.4.20.2. Financials
14.4.20.3. Developments
14.4.20.4. Strategic Outlook
